COMBIVENT RESPIMAT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for COMBIVENT RESPIMAT (COMBIVENT RESPIMAT).
Combination of ipratropium bromide (anticholinergic) and albuterol sulfate (beta-2 adrenergic agonist). Ipratropium inhibits muscarinic acetylcholine receptors, reducing bronchoconstriction and mucus secretion. Albuterol stimulates beta-2 receptors, relaxing bronchial smooth muscle and increasing cAMP.
| Metabolism | Ipratropium: partially metabolized by ester hydrolysis to inactive metabolites; Albuterol: primarily metabolized by sulfotransferase (SULT1A3) to albuterol 4'-O-sulfate. |
| Excretion | Ipratropium: primarily fecal (70-90%) via biliary excretion, renal excretion accounts for 10-20%. Salbutamol: 60-70% renal as unchanged drug and metabolites, 30-40% fecal via biliary excretion. |
| Half-life | Ipratropium: terminal half-life approximately 1.6 hours. Salbutamol: terminal half-life 3.8-6 hours (mean 4.6 hours). Clinically, inhalation allows direct airway delivery; systemic half-life not primarily responsible for bronchodilator effect. |
| Protein binding | Ipratropium: 0-9% (minimal). Salbutamol: 10-15% primarily to albumin. |
| Volume of Distribution | Ipratropium: 4.6 L/kg (large Vd indicates extensive tissue distribution). Salbutamol: 4-6 L/kg (high Vd reflects distribution into tissues). |
| Bioavailability | Inhalation: 7-14% of delivered dose reaches systemic circulation (ipratropium 7%, salbutamol 13-14%). Oral bioavailability: ipratropium <5%, salbutamol 30-40%. |
| Onset of Action | Inhalation: 15-20 minutes for significant bronchodilation. |
| Duration of Action | 4-6 hours (bronchodilation). Clinical note: duration may be shorter in acute bronchospasm. |
| Molecular Weight | 412.15 |
Two inhalations (ipratropium 18 mcg and albuterol 103 mcg per inhalation) via oral inhalation four times daily. Maximum: 12 inhalations per 24 hours.
| Dosage form | SPRAY, METERED |
| Renal impairment | No specific dose adjustment recommended for renal impairment. Use caution in patients with severe renal impairment (CrCl <30 mL/min) due to potential for systemic accumulation. |
| Liver impairment | No specific dose adjustment recommended for hepatic impairment. Use caution in severe hepatic impairment (Child-Pugh class C) as safety data are limited. |
| Pediatric use | Not established for children under 18 years. Safety and efficacy have not been determined in pediatric patients. |
| Geriatric use | No specific dose adjustment recommended. Use with caution due to increased sensitivity to anticholinergic effects (e.g., urinary retention, constipation) and beta-agonist effects (e.g., tremor, tachycardia). Monitor renal function as elderly are more prone to decreased renal function. |
| 1st trimester | Avoid use during first trimester unless potential benefit outweighs risk; limited human data, animal studies show some risk. |
| 2nd trimester | Use only if clearly needed; ipratropium and albuterol have some evidence of safety but not well-studied in combination. |
| 3rd trimester | Albuterol may inhibit uterine contractions and cause maternal tachycardia; ipratropium safety unknown; use with caution. |
Clinical note
Comprehensive clinical and safety monograph for COMBIVENT RESPIMAT (COMBIVENT RESPIMAT).
| Placental transfer | Albuterol crosses placenta; ipratropium likely crosses but minimal systemic absorption from inhalation limits fetal exposure. |
| Breastfeeding | Ipratropium is not absorbed orally and unlikely to reach infant; albuterol excreted in breast milk in small amounts, but risk of adverse effects is low if inhaled doses are used. Consider benefits of breastfeeding versus potential risk. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to any component (ipratropium, albuterol, or atropine-like substances)History of hypersensitivity to soy lecithin or related food products (for some formulations)
| Precautions | Paradoxical bronchospasm, Immediate hypersensitivity reactions (anaphylaxis, urticaria), Cardiovascular effects (increased heart rate, hypertension, QT prolongation), Use with caution in patients with glaucoma, urinary retention, or prostatic hypertrophy, Exacerbation of diabetes and ketoacidosis with albuterol, Hypokalemia with high doses of albuterol, Not for acute deterioration or rescue therapy |
| Food/Dietary | No specific food interactions reported. Avoid excessive caffeine or stimulants as they may increase risk of hypokalemia and cardiac effects. |
Loading safety data…
| Lactation Rating | L2 (Probably Compatible) |
| Teratogenic Risk | Ipratropium bromide and albuterol sulfate. Ipratropium: No teratogenic effects in animal studies; minimal systemic absorption suggests low fetal risk. Albuterol: Inhaled beta-agonists are not associated with major malformations; risk of preterm labor and maternal hyperglycemia. First trimester: No known teratogenicity. Second/third trimesters: May cause fetal tachycardia, hypoglycemia, and hypocalcemia if used near delivery. Overall, use only if clearly needed. |
| Fetal Monitoring | Monitor maternal pulmonary function, fetal heart rate, and uterine activity in patients with asthma exacerbations. Assess for signs of maternal hyperglycemia, hypokalemia, and tremors. In third trimester, monitor for preterm labor and fetal distress. Performance of fetal nonstress test or biophysical profile if indicated. |
| Fertility Effects | Albuterol: No known adverse effects on human fertility. Ipratropium: No data on fertility impairment. Animal studies show no fertility compromise. |
| Clinical Pearls | Combivent Respimat is a fixed-dose combination of ipratropium bromide and albuterol sulfate for maintenance treatment of COPD. It should not be used for acute exacerbations; short-acting beta-agonists are preferred. The Respimat device delivers a slow-moving aerosol; proper inhalation technique is critical. Monitor for paradoxical bronchospasm, atrial fibrillation, and hypokalemia, especially in patients with cardiac disease. May increase intraocular pressure in patients with narrow-angle glaucoma; avoid spraying into eyes. |
| Patient Advice | Use exactly as prescribed; do not use more puffs than directed. · Do not use for sudden shortness of breath; have a rescue inhaler available. · Prime the Respimat inhaler by releasing 3 sprays into the air before first use or after not using for more than 3 days. · Do not spray into eyes; if contact occurs, rinse with water and seek medical attention if symptoms persist. · Continue using regularly even if feeling well; do not stop without consulting your doctor. · Seek emergency care if breathing worsens or you develop hives, swelling, or severe dizziness. |